6th Oligonucleotide & Precision Therapeutics Release Time：2021-03-30 - 2021-03-31

HitGen has established its own capabilities for early stage research & discovery of small RNA drugs. As shown below, we have assembled a group of experts and talents in the field to substantially support RNA interference (RNAi)-based therapeutics development from initial RNA design to preclinical candidate nomination (PCC) stage, including RNA bioinformatics, oligonucleotide chemistry, in vitro and in vivo functional evaluation. Endorsed by our intensive experience in the DNA-Encoding Library (DEL) technology and Nucleic Acid Chemistry, we are able to provide comprehensive and one-stop services, such as target survey analysis, rational design of highly potent small RNAs, a wide variety of phosphoramidites, synthesis and chemical modification/conjugation of various nucleic acids, process development, functional screening in in vitro cell culture as well in vivo animal models.

HitGen will attend the meeting and the interactive event offers scientific and networking opportunities for those working in drug research and development. 

To oarrange a meeting with HitGen,  please call +86-28-85197385, +1-508-840-9646 

For media inquiries: media@hitgen.com

For investor inquiries: investors@hitgen.com 

For business development: bd@hitgen.com